Objective: Thoracic aortic aneurysms (TAAs) develop by a multifactorial process involving maladaptive signaling pathways that alter the aortic vascular environment. Transforming growth factor-beta (TGF-β) has been implicated in regulating the structure and composition of the extracellular matrix by differential activation of various intracellular signaling pathways. However, whether and to what degree TGF-β signaling contributes to TAA development remains unclear. Accordingly, the hypothesis that alterations in TGF-β signaling occur during aneurysm formation was tested in a murine model of TAA. Methods: TAAs were surgically induced in mice (C57BL/6J) and aortas were analyzed at predetermined time points (1, 2, and 4 weeks post-TAA induction). Quantitative real-time PCR (QPCR) was performed to evaluate the expression of 84 relevant TGF-β superfamily genes, and the protein levels of key signaling intermediates were measured by immunoblotting. Results were compared to unoperated reference control mice. Results: QPCR revealed increased expression of TGF-β superfamily ligands (Gdf-2, -6, -7, Inhba), ligand inhibitors (Bmper, Chrd, Gsc), and transcriptional regulators (Dlx2, Evi1), among other genes (Cdkn2b, Igf1, IL-6). Protein levels of TGF-β receptorII, Smad2, Smad1/5/8, phospho-Smad1/5/8, and Smurf1 were increased from control values post-TAA induction. Both TGF-β receptorI and Smad4 were decreased from control values, while ALK-1 levels remained unchanged. Conclusions: These alterations in the TGF-β pathway suggest a mechanism by which primary signaling is switched from a TGF-βRI/Smad2-dependent response, to an ALK-1/Smad1/5/8 response, representing a significant change in signaling outcome, which may enhance matrix degradation.

1.
Isselbacher EM: Thoracic and abdominal aortic aneurysms. Circulation 2005;111:816–828.
2.
Thompson RW: Reflections on the pathogenesis of abdominal aortic aneurysms. Cardiovasc Surg 2002;10:389–394.
3.
Liapis CD, Paraskevas KI: The pivotal role of matrix metalloproteinases in the development of human abdominal aortic aneurysms. Vasc Med 2003;8:267–271.
4.
Thompson RW, Geraghty PJ, Lee JK: Abdominal aortic aneurysms: basic mechanisms and clinical implications. Curr Probl Surg 2002;39:110–230.
5.
Tamarina NA, McMillan WD, Shively VP, Pearce WH: Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery 1997;122:264–271; discussion 271–272.
6.
Bobik A: Transforming growth factor-betas and vascular disorders. Arterioscler Thromb Vasc Biol 2006;26:1712–1720.
7.
Ghosh AK: Factors involved in the regulation of type I collagen gene expression: implication in fibrosis. Exp Biol Med (Maywood) 2002;227:301–314.
8.
Massagué J: TGFbeta signaling: receptors, transducers, and Mad proteins. Cell 1996;85:947–950.
9.
Massagué J: How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000;1:169–178.
10.
Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, et al: Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167–4171.
11.
Shi Y, Massagué J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003;113:685–700.
12.
Feng XH, Derynck R: Specificity and versatility in TGF-beta signaling through Smads. Annu Rev Cell Dev Biol 2005;21:659–693.
13.
Moustakas A, Souchelnytskyi S, Heldin CH: Smad regulation in TGF-beta signal transduction. J Cell Sci 2001;114:4359–4369.
14.
Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003;425:577–584.
15.
Moustakas A, Heldin CH: Non-Smad TGF-beta signals. J Cell Sci 2005;118:3573–3584.
16.
Hasham SN, Willing MC, Guo DC, Muilenburg A, He R, Tran VT, Scherer SE, Shete SS, Milewicz DM: Mapping a locus for familial thoracic aortic aneurysms and dissections (TAAD2) to 3p24–25. Circulation 2003;107:3184–3190.
17.
Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, Meyers J, Leitch CC, Katsanis N, Sharifi N, Xu FL, Myers LA, Spevak PJ, Cameron DE, De Backer J, Hellemans J, Chen Y, Davis EC, Webb CL, Kress W, Coucke P, Rifkin DB, De Paepe AM, Dietz HC: A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005;37:275–281.
18.
Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC: Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003;33:407–411.
19.
Pannu H, Fadulu VT, Chang J, Lafont A, Hasham SN, Sparks E, Giampietro PF, Zaleski C, Estrera AL, Safi HJ, Shete S, Willing MC, Raman CS, Milewicz DM: Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation 2005;112:513–520.
20.
Ikonomidis JS, Gibson WC, Gardner J, Sweterlitsch S, Thompson RP, Mukherjee R, Spinale FG: A murine model of thoracic aortic aneurysms. J Surg Res 2003;115:157–163.
21.
Jones JA, Barbour JR, Lowry AS, Bouges S, Beck C, McClister DM Jr, Mukherjee R, Ikonomidis JS: Spatiotemporal expression and localization of matrix metalloproteinase-9 in a murine model of thoracic aortic aneurysm. J Vasc Surg 2006;44:1314–1321.
22.
Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L: Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 1998;82:482–495.
23.
Francis-West PH, Parish J, Lee K, Archer CW: BMP/GDF-signalling interactions during synovial joint development. Cell Tissue Res 1999;296:111–119.
24.
Wolfman NM, Hattersley G, Cox K, Celeste AJ, Nelson R, Yamaji N, Dube JL, DiBlasio-Smith E, Nove J, Song JJ, Wozney JM, Rosen V: Ectopic induction of tendon and ligament in rats by growth and differentiation factors 5, 6, and 7, members of the TGF-beta gene family. J Clin Invest 1997;100:321–330.
25.
Molloy CJ, Taylor DS, Pawlowski JE: Novel cardiovascular actions of the activins. J Endocrinol 1999;161:179–185.
26.
Nakashima A, Tamura M: Regulation of matrix metalloproteinase-13 and tissue inhibitor of matrix metalloproteinase-1 gene expression by WNT3A and bone morphogenetic protein-2 in osteoblastic differentiation. Front Biosci 2006;11:1667–1678.
27.
Hannon GJ, Beach D: p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994;371:257–261.
28.
Chiba S, Takeshita K, Imai Y, Kumano K, Kurokawa M, Masuda S, Shimizu K, Nakamura S, Ruddle FH, Hirai H: Homeoprotein DLX-1 interacts with Smad4 and blocks a signaling pathway from activin A in hematopoietic cells. Proc Natl Acad Sci USA 2003;100:15577–15582.
29.
Xu SC, Harris MA, Rubenstein JL, Mundy GR, Harris SE: Bone morphogenetic protein-2 (BMP-2) signaling to the Col2alpha1 gene in chondroblasts requires the homeobox gene Dlx-2. DNA Cell Biol 2001;20:359–365.
30.
Bertrand-Philippe M, Ruddell RG, Arthur MJ, Thomas J, Mungalsingh N, Mann DA: Regulation of tissue inhibitor of metalloproteinase 1 gene transcription by RUNX1 and RUNX2. J Biol Chem 2004;279:24530–24539.
31.
Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, Yazaki Y, Matsumoto K, Hirai H: The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 1998;394:92–96.
32.
Ikonomidis JS, Gibson WC, Butler JE, McClister DM, Sweterlitsch SE, Thompson RP, Mukherjee R, Spinale FG: Effects of deletion of the tissue inhibitor of matrix metalloproteinases-1 gene on the progression of murine thoracic aortic aneurysms. Circulation 2004;110(11 Suppl 1):II268–II273.
33.
Bloor CA, Knight RA, Kedia RK, Spiteri MA, Allen JT: Differential mRNA expression of insulin-like growth factor-1 splice variants in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Care Med 2001;164:265–272.
34.
Okazaki R, Durham SK, Riggs BL, Conover CA: Transforming growth factor-beta and forskolin increase all classes of insulin-like growth factor-I transcripts in normal human osteoblast-like cells. Biochem Biophys Res Commun 1995;207:963–970.
35.
Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BK, Park YK, Chi SG: Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene 2003;22:4314–4332.
36.
Zhang XL, Topley N, Ito T, Phillips A: Interleukin-6 regulation of transforming growth factor (TGF)-beta receptor compartmentalization and turnover enhances TGF-beta1 signaling. J Biol Chem 2005;280:12239–12245.
37.
Dawson J, Cockerill GW, Choke E, Belli AM, Loftus I, Thompson MM: Aortic aneurysms secrete interleukin-6 into the circulation. J Vasc Surg 2007;45:350–356.
38.
Middleton RK, Lloyd GM, Bown MJ, Cooper NJ, London NJ, Sayers RD: The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: a protein array study. J Vasc Surg 2007;45:574–580.
39.
Sehgal PB, Tamm I: Interleukin-6 enhances motility of breast carcinoma cells. EXS 1991;59:178–193.
40.
Kusano K, Miyaura C, Inada M, Tamura T, Ito A, Nagase H, Kamoi K, Suda T: Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 1998;139:1338–1345.
41.
Lin T, Zhang W, Fan Y, Mulholland M: Interleukin-1beta and interleukin-6 stimulate matrix metalloproteinase-9 secretion in cultured myenteric glia. J Surg Res 2007;137:38–45.
42.
Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, Miyazono K: Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem 2001;276:12477–12480.
43.
Moren A, Imamura T, Miyazono K, Heldin CH, Moustakas A: Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases. J Biol Chem 2005;280:22115–22123.
44.
Chen YG, Massague J: Smad1 recognition and activation by the ALK1 group of transforming growth factor-beta family receptors. J Biol Chem 1999;274:3672–3677.
45.
Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, Li E: Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 2000;97:2626–2631.
46.
Goumans MJ, Lebrin F, Valdimarsdottir G: Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways. Trends Cardiovasc Med 2003;13:301–307.
47.
Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S, ten Dijke P: Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell 2003;12:817–828.
48.
Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P: Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. Embo J 2002;21:1743–1753.
49.
Bertolino P, Deckers M, Lebrin F, ten Dijke P: Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest 2005;128:585S–590S.
50.
Fernandez LA, Sanz-Rodriguez F, Blanco FJ, Bernabeu C, Botella LM: Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-beta signaling pathway. Clin Med Res 2006;4:66–78.
51.
Rundhaug JE: Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005;9:267–285.
52.
Choke E, Cockerill GW, Dawson J, Wilson RW, Jones A, Loftus IM, Thompson MM: Increased angiogenesis at the site of abdominal aortic aneurysm rupture. Ann NY Acad Sci 2006;1085:315–319.
53.
Miwa K, Nakashima H, Aoki M, Miyake T, Kawasaki T, Iwai M, Oishi M, Kataoka K, Ohgi S, Ogihara T, Kaneda Y, Morishita R: Inhibition of ets, an essential transcription factor for angiogenesis, to prevent the development of abdominal aortic aneurysm in a rat model. Gene Ther 2005;12:1109–1118.
54.
Paik DC, Fu C, Bhattacharya J, Tilson MD: Ongoing angiogenesis in blood vessels of the abdominal aortic aneurysm. Exp Mol Med 2004;36:524–533.
55.
Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D: GeneCards: encyclopedia for genes, proteins and diseases. Rehovot, Weizmann Institute of Science, 1997. www.genecards.org.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.